Category: News

7^th BioPharma ASIA Convention 2014 was held in Suntec Singapore Convention & Exhibition Centre Level 4, halls 403-405 Singapore during 10-13 March 2014. This event is the biggest convention to pharma, biotech and R&D community to exhibit in ASIA.

Prodia DiaCRO Laboratories as silver sponsor of BioPharma ASIA Convention 2014 was opening a booth No. D14. It was the 5^th occasion to PT. Prodia DiaCRO Laboratories as the first and the only local CRO in Indonesia to conduct full service Clinical Trial to attend and exhibit a booth in this event.

On Wednesday, 12^th March 2014, President Director of Prodia DiaCRO Laboratories, Mrs. Endang Hoyaranda, convey a topic titled “The Role of SMO: Feeling The Gaps Towards High Quality Studies.”

Indonesia has such a huge potential as a place to conduct clinical trial. Therefore, we welcome worldwide sponsors to be able to bring clinical trial projects to perform in Indonesia.

PT. Prodia DiaCRO Laboratories has established trial site capacity building program with RSUP Dr. Wahidin Sudirohusodo, RS Hasanuddin University and Medical Faculty of Hasanuddin University Makassar. The signed MoU took place in Medical Faculty of Hasanuddin University Makassar on 22^nd January 2014

Development of SMO in Prodia has brought the trial site capacity building program established between PT. Prodia DiaCRO Laboratories with RSUP Dr. Hasan Sadikin. The signed Memorandum of Understanding (MoU) between two parties took place in RSUP Dr. Hasan Sadikin on 13^th January 2014. The MoU was signed by Drs. Gunawan Prawira Soeharto as Director of PT. Prodia DiaCRO Laboratories and dr. H. Bayu Wahyudi, SpOG, MPHM, MHKes as Managing Director of RSUP. Dr. Hasan Sadikin Bandung. This MoU signals a commitment by both institution to support high quality Clinical Trial in Bandung, Indonesia.

At the end of 2012, PT. Prodia DiaCRO Laboratories has established trial site capacity building with RSUD Prof. Dr. Margono Soekarjo and Medical Faculty of Jend. Soedirman University which placed in Purwokerto, Central of Java, as the assurance to conduct an effective clinical trial. The Memorandum of Understanding signed in October 2012 between three parties. Hopefully this MoU brings strategic and beneficial in the future.

Prodia Clinical Laboratory – which is the largest and the best independent laboratory in Indonesia achieved The College of American Pathologist (CAP) accreditation in July 2012; making it the first and the only one Clinical Laboratory in Indonesia and together with 7000’s reputable clinical laboratory worldwide to hold this accreditation. The CAP laboratory accreditation is an internationally recognized program that is accepted as the gold standard for quality to improve patient safety.

Prodia Clinical Laboratory provides a wide range of laboratory testing services. Our priority is to establish quality from the time subjects are prepared for specimen collection up to final data analysis. As the leading company, Prodia was the first clinical laboratory in Indonesia to meet ISO 9001, ISO 15189, and The National Glycohemoglobin Standardization Program (NGSP) certification in level 1 for HbA1c standardization.

As the local market leader, since 1997, Prodia has been playing a significant role in contributing the clinical trial both locally and globally. As the only CAP accredited clinical laboratory in Indonesia, Prodia is dedicated to intensify the participation on the world stage clinical trial to establish Indonesia as a clinical trial center of excellent.

SINGAPORE and JAKARTA, INDONESIA – November 30, 2011 – Quintiles today announced an expanded partnership with Jakarta-based Prodia Clinical Laboratory through its sister company Prodia the CRO, to facilitate rapid testing of  samples from patients in clinical trials in Indonesia.  The partnership will help Quintiles’ biopharmaceutical customers establish the benefits of new medicines in Indonesian patients .

Under the agreement, Prodia will provide Quintiles with exclusive access to its central laboratory services for a two-year period.

“This agreement demonstrates Quintiles’ commitment to improving human health in Indonesia by participating in global clinical research and development,” said Kerry Strydom, general manager of Quintiles Australia, New Zealand, Indonesia and Philippines.  “Indonesia has an ethnically diverse population of 240 million.  Major health issues in the region include infectious and non-communicable diseases, with mental health problems and tobacco-related illnesses also on the rise.

“As new and improved medicines are developed for these conditions, it’s important that they are studied in populations for whom they are intended, including Indonesian patients.”

Prodia the CRO President, Gunawan Prawiro Suharto said, “As the local market leader in laboratory services, Prodia is delighted to partner with Quintiles to help establish Indonesia as a true centre of excellence for delivery of clinical trials. We look forward to working with Quintiles and its global biopharma customers to develop novel therapies.”

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 24,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics.

Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant.  In Asia Pacific alone, Quintiles has 5,000 employees in 15 countries, and was voted 2010 Asia Pacific CRO of the Year by Frost & Sullivan, and Best CRO by Biopharma Asia Pacific 2011. For more information, please visit www.quintiles.com.

About Prodia Clinical Laboratory

Prodia Clinical Laboratory, one of the largest and the best clinical laboratories in Asia for nearly 39 years, provides a wide range of laboratory testing services. Quality is first priority from the time subjects are prepared for specimens collection up to final data analysis.  Prodia was the first clinical laboratory in Indonesia to meet with ISO 9001 & ISO 15189 standards, and has recently obtained certification from the National Glycohemoglobin Standardisation Program (NGSP) Level 1 for HbA1c standardisation.

It is currently in the process of obtaining CAP (College of American Pathologists) accreditation which is expected to be completed early 2012. It has received awards as National Top Brand for the last 3 consecutive years, and owns a network of 110 branches nationwide to cover patient sampling at any needed site in the country. It has been working in the clinical trial area for nearly 15 years, and later established a sister CRO company. To learn more about Prodia Labs and Prodia the CRO, visit their websites at www.prodia.co.id and www.prodiathecro.com.